news
Press release
 
May 15, 2017
Precision Registry Data On Robotic-Assisted PCI Presented During Late Breaking Clinical Trial Session at SCAI 2017

Launched PRECISION GRX Study for market surveillance of second generation CorPath GRX System

WALTHAM, MA — MAY 15, 2017 — Corindus Vascular Robotics, Inc. [NYSE MKT: CVRS] announced today the latest post-market findings from the PRECISION Registry at the 2017 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions. "Efficacy and Safety Outcomes of Radial-vs Femoral-Access Robotic Percutaneous Coronary Intervention: Final Results of the Multicenter PRECISION Registry” was presented on behalf of the PRECISION investigators by Ehtisham Mahmud, M.D., FSCAI of UC San Diego School of Medicine, on Friday, May 12, during the Late Breaking Clinical Trials Session. Findings show a high success rate of both radial and femoral access robotic-assisted percutaneous coronary interventions (PCI).

"The selection of this study as a Late Breaking Clinical Trial at SCAI 2017 is a testament to the significance robotics will have in invasive cardiology," stated Dr. Mahmud. "My early experience with the CorPath 200 System demonstrated feasibility, safety and procedural effectiveness of robotic PCI to be comparable to the manual approach, even in complex and radial access PCI. I am excited to lead the PRECISION GRX Registry to further demonstrate the applicability and value of CorPath GRX in complex and radial cases."

The PRECISION Study, a multicenter post-market registry for the evaluation of the effectiveness of the CorPath® 200 System, aimed to collect data on the routine use of the CorPath 200 System in PCIs. Giora Weisz, M.D., Associate Professor of Medicine at Columbia University Medical Center and at the Hebrew University, was the Principal Investigator for the PRECISION Registry. Results showed that 754 patients with an aggregate of 949 lesions were treated with robotic PCI using transradial access in 452 (59.9%) and transfemoral access in 298 (39.5%). Technical (88.6% TRA vs 82.4% TFA; p=0.0224) and clinical success rates (98.9% TRA vs 94.9% TFA; p=0.0019) for both groups were high.

Corindus is now launching the PRECISION GRX Study, a post-market registry to continue market surveillance of its second generation CorPath GRX System. Dr. Mahmud has been named as the Principal Investigator for the PRECISION GRX Study. The CorPath GRX System offers improvements in procedural control, enhanced workflow and radiation protection for physicians, patients and staff.

About Corindus Vascular Robotics, Inc.

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."

For additional information, visit www.corindus.com, and follow @CorindusInc.

Forward Looking Statements

Statements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Corindus to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward looking statements. In addition to statements that explicitly describe such risks and uncertainties, readers are urged to consider statements in the conditional or future tenses or that includes terms such as "believes," "belief," "expects," "estimates," "intends," "anticipates" or "plans" to be uncertain and forward-looking. Forward-looking statements may include comments as to Corindus’ beliefs and expectations as to future event

Examples of such statements include statements:

  • that the level of precision that can be attained using the CorPath GRX technology, combined with the potential for remote capabilities in the future, will both expand and improve how patients are treated;
  • that Corindus has entered a transformational period with a focus on expanding its reach to partner with hospitals to build robotic programs globally;
  • that the successful completion of these procedures at Fu Wai Hospital is the first step in Corindus' growth strategy within China; and that
  • the precise positioning enhancements to the CorPath platform that allows physicians to adjust guide catheters during PCI procedures may expand the use of the CorPath GRX System to more complex cases.

Media Contacts:

Corindus Vascular Robotics, Inc.

Kate Stanton
(508) 653-3335 ext. 200
kate.stanton@corindus.com

Investor Contact:

Lynn Pieper Lewis
(415) 937-5402
ir@corindus.com
 
close the window

Please complete the form below in order to download the content.








right
close the window

Please complete the form below in order to download the content.







close the window

Please fill out this brief form to subscribe to our email newsletter.





close the window

Please complete the form below and a member of our Clinical team will contact you.






close the window

Please complete the form below in order to download the content.







close the window